Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Efgartigimod Shows Sustained Efficacy in Myasthenia Gravis Subtypes

(MedPage Today) -- Intravenous efgartigimod (Vyvgart) continued to demonstrate efficacy and safety in patients with generalized myasthenia gravis who did not have detectable anti-acetylcholine receptor (AChR) antibodies, data from the open-label...

Efgartigimod Shows Sustained Efficacy in Myasthenia Gravis Subtypes

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine

More from Thursday 1 October →